1. Market Research
  2. > Pharmaceutical Market Trends
  3. > China Pharmaceutical Distribution Industry Report, 2013

China Pharmaceutical Distribution Industry Report, 2013

  • April 2014
  • -
  • Research In China
  • -
  • 111 pages

Thanks to the continuous advancement in new medical reform, China’s pharmaceutical distribution industry has maintained a fairly rapid growth in recent years, with the sales value showed a CAGR of roughly 20% in 2005-2013. As the leading players in China’s pharmaceutical distribution industry, Shanghai Pharma, Jointown and China National Accord Medicines achieved the revenue of RMB58.1 billion , RMB24.8 billion , RMB15.8 billion, respectively, in the first three quarters of 2013.

In terms of drug categories, western medicine constitutes the first major category in Chinese medicine distribution market, accounting for approximately 70% of total revenue from Chinese pharmaceutical products during 2012-2013. Then what comes the next are Chinese patent medicine and traditional Chinese medicinal materials, which occupied 16.8% and 4.5%, respectively, of total revenue. In terms of distribution channels, the proportion of China's drug retail terminal and hospital terminal market share stood at 1:4.

The concentration of Chinese pharmaceutical distribution industry is relatively low. Take pharmaceutical chain market for example. In recent years, China's top 100 pharmaceutical chain enterprises have seen a rise in market share, but still less than 40%. In 2013, China's top 100 pharmaceutical chain enterprises posted a total of RMB98.36 billion in sales, up 11.9% from a year earlier. Guoda Drugstore under China National Accord Medicines still firmly held the first place in China's top 100 pharmaceutical chain enterprises, with the sales value for 2013 hitting RMB5.7 billion, a roughly 20% increase.

At present, Chinese pharmaceutical B2C sales model occupies a small market share in pharmaceutical terminal market, but grows rapidly. As of March 2014, a total of 235 companies in China have gained Qualification Certificate for Online Drug Trading Services, including 162 online pharmacies. In 2013, Chinese pharmaceutical B2C market presented the explosive growth, with transaction scale hitting RMB4.26 billion, up 166% from a year earlier. But due to policy restriction, consumers now fail to buy prescription drugs through pharmaceutical B2C, and medical insurance is not available, which would, to a certain extent, restrict the development of Chinese pharmaceutical B2C market.

China Pharmaceutical Distribution Industry Report, 2013-2017 involves the following:

Business model, operating environment, market size, sales structure, etc of Chinese drug distribution industry;
Stores, customers, sales structue and online pharmacies, etc of Top 100 Chinese drugstore chains;
Operation, profits, etc of 13 listed companies in Chinese pharmaceutical distribution industry.

Table Of Contents

China Pharmaceutical Distribution Industry Report, 2013
1. Overview of Pharmaceutical Distribution Industry
1.1 Definition
1.2 Industry Chain
1.3 Strength and Weakness of Pharmaceutical Chain Enterprises
1.3.1 Strength of Pharmaceutical Chain Enterprises
1.3.2 Weakness of Pharmaceutical Chain Enterprises

2. Development of China Pharmaceutical Distribution Industry
2.1 Pharmaceutical Distribution Industry
2.2 Industry Environment
2.2.1 China's Healthcare Spending
2.2.2 China's Healthcare Organizations
2.2.3 Contribution of Pharmaceutical Distribution Industry to GDP, Taxation and Employment
2.3 Relevant Policies
2.4 Market Size
2.5 Development Structure
2.5.1 Sales Structure
2.5.2 Regional Structure
2.5.3 Ownership Structure
2.5.4 Distribution Structure

3. China's Top 100 Pharmacy Chains
3.1 Sales Scale
3.2 Store Analysis
3.2.1 Store Size
3.2.2 Sales per Unit Area
3.2.3 Pharmacies with Insurance Coverage
3.3 Consumer Analysis
3.3.1 Membership
3.3.2 Per Customer Transaction
3.3.3 Per Product Transaction
3.3.4 Average Sales Price
3.4 Classification
3.4.1 Total Number of Drug Specifications
3.4.2 Prescription Drugs
3.4.3 OTC Drugs
3.4.4 Traditional Chinese Medicine Decoction Pieces
3.4.5 Medical Devices
3.4.6 Food/Health Care Products
3.4.7 Products with Private Brand or High Gross Profit
3.5 Single-store Analysis of Chinese Pharmacies
3.6 Online Pharmacies
3.6.1 Scale of China Pharmaceutical B2C
3.6.2 Characteristics of China Pharmaceutical B2C
3.6.3 Relevant Policies

4. Key Enterprises
4.1 China National Accord Medicines
4.1.1 Profile
4.1.2 Operation
4.1.3 Revenue Structure
4.1.4 Gross Margin
4.1.5 Major Clients
4.2 Nanjing Pharmaceutical Co., Ltd (NPC)
4.2.1 Profile
4.2.2 Operation
4.2.3 Revenue Structure
4.2.4 Gross Margin
4.2.5 Major Clients
4.3 Chongqing Tongjunge
4.3.1 Profile
4.3.2 Operation
4.3.3 Revenue Structure
4.3.4 Gross Margin
4.3.5 Major Clients
4.4 Shanghai No.1 Pharmacy
4.4.1 Profile
4.4.2 Operation
4.4.3 Revenue Structure
4.4.4 Gross Margin
4.4.5 Major Clients
4.5 China National Medicines
4.5.1 Profile
4.5.2 Operation
4.5.3 Revenue Structure
4.5.4 Gross Margin
4.5.5 Major Clients
4.6 Huadong Medicine
4.6.1 Profile
4.6.2 Operation
4.6.3 Revenue Structure
4.6.4 Gross Margin
4.6.5 Major Clients
4.7 Cachet
4.7.1 Profile
4.7.2 Operation
4.7.3 Revenue Structure
4.7.4 Gross Margin
4.7.5 Major Clients
4.8 Jointown
4.8.1 Profile
4.8.2 Operation
4.8.3 Revenue Structure
4.8.4 Gross Margin
4.8.5 Major Clients
4.9 Realcan Pharmaceutical
4.9.1 Profile
4.9.2 Operation
4.9.3 Revenue Structure
4.9.4 Gross Margin
4.9.5 Major Clients
4.10 Shanghai Pharma
4.10.1 Profile
4.10.2 Operation
4.10.3 Revenue Structure
4.10.4 Gross Margin
4.10.5 Major Clients
4.11 Zhejiang Int'l Group
4.11.1 Profile
4.11.2 Operation
4.11.3 Revenue Structure
4.11.4 Gross Margin
4.11.5 Major Clients
4.12 Zhejiang Zhenyuan
4.12.1 Profile
4.12.2 Operation
4.12.3 Revenue Structure
4.12.4 Gross Margin
4.12.5 Major Clients
4.13 CNPIC
4.13.1 Profile
4.13.2 Operation
4.13.3 Revenue Structure
4.13.4 Gross Margin
4.13.5 Major Clients

5. Summary and Forecast
5.1 Summary
5.2 Forecast

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers
Prostate Cancer Pricing, Reimbursement, and Access

Prostate Cancer Pricing, Reimbursement, and Access

  • $ 7500
  • Industry report
  • July 2016
  • by Datamonitor Healthcare

Novel antiandrogens will need to present risk-sharing agreements in EU markets, while discussing contracting with US payers to ensure a competitive advantage. Vaccines suffer from inconclusive response ...

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

  • $ 7000
  • Industry report
  • August 2016
  • by Frost & Sullivan

Emerging Business Models Drive Transformation The key objective of this research is to provide in-depth knowledge of the major global pharmaceutical CMO market segments—active pharmaceutical ingredients ...

IMS World Review Executive™ 2016

IMS World Review Executive™ 2016

  • $ 6860
  • Industry report
  • July 2016
  • by IMS Health

IMS World Review ExecutiveTM 2016 provides essential insights into worldwide sales of the pharmaceutical market, interlocking market trends and sales analysis from 2011 to 2015, including the breakdown ...


Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.